Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results
Date:5/15/2009

idates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

                                -- Tables Follow --

                                 PHARMATHENE, INC.

                            CONSOLIDATED BALANCE SHEETS

                                               March 31,     December 31,
                                                 2009            2008
                                             (unaudited)

                         ASSETS
    Current assets:
      Cash and cash equivalents               $17,245,420     $19,752,404
      Restricted cash                           9,000,000      12,000,000
      Short-term investments                    6,773,594       3,190,912
      Accounts receivable                       9,961,596       8,890,077
      Other receivables                         1,089,857       1,391,512
      Prepaid expenses and other current assets   960,939         917,125
    Total current assets                       45,031,406      46,142,030

    Long-term restricted cash                           -       1,250,000
    Property and equipment, net                 5,211,214       5,313,219
    Patents, net                                  875,098         925,489
    Other long-term assets                        223,026         220,531
    Deferred costs                                 34,643          37,092
    Goodwill                                    2
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences ... medicine company focused on the development of autologous cell ... of the University of Calgary in conjunction with co-authors ... which further validates the company,s ongoing clinical research using ... of pattern baldness. The paper entitled " ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... Washington, D.C. - With the opening of a ... Gov. Jim Doyle again urged Senators to overturn ... research. , ,During a morning visit to the West Salem home ... Doyle again used the backdrop of a Wisconsin family with a ...
... the banking and payments technology subsidiary of Marshall ... a new cash-management division and the appointment of its ... , ,Kasik will run the division, which will allow ... income statement items, payables, and receivables with full accounting ...
... - The United States Senate, by a vote of 63-37, ... ban on new federal funding for embryonic stem cell research, setting ... short of the 67 votes needed to override a veto, which ... bill, known as the Stem Cell Research Enhancement Act , ...
Cached Biology Technology:Doyle urges Senate to loosen stem cell restrictions 2Doyle urges Senate to loosen stem cell restrictions 3Doyle urges Senate to loosen stem cell restrictions 4Senate approves bill to expand stem cell funding 2
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... Galton-Darwin-Wedgwood pedigree was prepared by Harry Hamilton Laughlin, Director ... and exhibited at the Third International Congress of Eugenics ... A photograph of this poster has been discovered ... Missouri alongside a photograph of a poster of a ...
... are launching a new series of podcasts this week entitled ... Save Our Seas Foundation (SOSF), investigate various topics of ocean ... Sarah Castor-Perry, both members of the Naked Scientists team and ... With the help of expert guests, they ...
... an important military, communication, aviation, and shipping hub of ... Korea and the Philippines has resulted in the arrival ... his team will develop, demonstrate and facilitate the adoption ... will enable growers to transition away from the use ...
Cached Biology News:New 'Naked Scientists' series investigates our oceans 2
... known as ChemiArrayTM Mouse Cytokine Antibody ... current methodologies. Besides the ability to ... a more accurate reflection of active ... secreted cytokines, and no amplification step ...
... DNA Engine instrument is the cycler ... Unprecedented thermal uniformity and swappable blocks ... This rugged machine is ... a platform for new features and ...
... (MSTA) slides were designed to study protein expression ... species. Tissue slices from three different species ... then be treated as a single histological slide ... hybridization. This format allows a rapid ...
... Multiple Species Tissue Array (MSTA) slides were designed ... and tissues from multiple species. Tissue slices ... MSTA slide which can then be treated as ... or in situ hybridization. This ...
Biology Products: